

FOI 3274

2nd September 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

ENC: FOI 3274

Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st April 2025 to the end of June 2025, or latest 3-months for which data are available?

Response:

Please see below data for 08/05/25 to 08/08/25:

Name of medicine	Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	6
1.2 Apalutamide (Erleada)	<5
1.3 Cabazitaxel (Jevtana or generic cabazitaxel)	<5
1.4 Darolutamide (Nubeqa)	8
1.5 Enzalutamide (Xtandi)	103
1.6 Talazoparib (Talzenna)	<5
1.7 Docetaxel	27
1.8 Relugolix (Orgovyx, Ryeqo)	<5

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals

concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st April 2025 to the end of June 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
2.1 Docetaxel for prostate cancer	
2.2 Olaparib (Lynparza) for prostate cancer	
2.3 Talazoparib (Talzenna) for prostate cancer	
2.4 Relugolix (Orgovyx) for prostate cancer	

Response:

Unable to answer as data currently held cannot be linked to single diagnosis.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Unfortunately we are unable to provide the information you have requested as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. It has been estimated that it would take more than 18 hours to locate and retrieve the requested information. In order to obtain this information and it would exceed the £450 limit and is therefore cost prohibitive.

Q3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st April 2025 to the end of June 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated in Cycle 1 or Dose 1
3.1 Abiraterone (Zytiga or generic abiraterone)	
3.2 Apalutamide (Erleada)	
3.3 Cabazitaxel (Jevtana or generic cabazitaxel)	
3.4 Darolutamide (Nubeqa)	
3.5 Enzalutamide (Xtandi)	

Response:

Unable to answer as data currently held cannot be linked to individual cycle numbers

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Unfortunately we are unable to provide the information you have requested as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. It has been estimated that it would take more than 18 hours to locate and retrieve the requested information. In order to obtain this information and it would exceed the £450 limit and is therefore cost prohibitive.

Q4. How many patients were treated with the following combinations in the 3 months between 1st April 2025 to the end of June 2025, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle.

Name of medicine	<u>Total</u> Number patients treated	Number patients received <u>cycle 1</u> or <u>dose 1</u>
4.1 Darolutamide (Nubeqa) + Docetaxel + ADT		
4.2 Darolutamide (Nubeqa) + ADT		
4.2 Olaparib (Lynparza) + Abiraterone		

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide

Response:

Unable to answer as data currently held cannot be linked to individual cycle numbers.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Unfortunately we are unable to provide the information you have requested as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. It has been estimated that it would take more than 18 hours to locate and retrieve the requested information. In order to obtain this information and it would exceed the £450 limit and is therefore cost prohibitive.

Q5. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st April 2025 to the end of June 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
5.1 Abiraterone	
5.2 Enzalutamide	

Response:

Unable to answer as data currently held cannot be linked to single diagnosis

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

Unfortunately we are unable to provide the information you have requested as the cost of locating and retrieving the information exceeds the "appropriate limit" as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. It has been estimated that it would take more than 18 hours to locate and retrieve the requested information. In order to obtain this information and it would exceed the £450 limit and is therefore cost prohibitive.

Email: Foi.Team@Southerntrust.hscni.net